A 52-week study of gabapentin enacarbil in restless legs syndrome

Clinical Neuropharmacology

Volumn 34, Issue 1, 2011, Pages 8-16

  Ellenbogen, Aaron L ^a   Thein, Stephen G ^b   Winslow, David H ^c   Becker, Philip M ^d   Tolson, Jerry M ^e   Lassauzet, Marie Liesse ^f   Chen, Dan ^f  

^a Michigan Institute for Neurological Disorders   (United States)

^b Pacific Research Network   (United States)

^c Kentucky Neuroscience Research   (United States)

^d Sleep Medicine Associates of Texas PA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f XenoPort Inc   (United States)

Author keywords

efficacy; gabapentin enacarbil; long term; restless legs syndrome; safety

Indexed keywords

DIPHENHYDRAMINE; GABAPENTIN ENACARBIL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL CHEMISTRY; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

ADULT; AGED; CARBAMATES; CHRONIC DISEASE; FEMALE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79551574731     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182087d48     Document Type: Article

References (18)

1. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165(11):1286-1292.
2. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81(1):17-27.
3. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5(1):9-14.
4. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62(9): 1377-1381.
5. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30(5):249-255.
6. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(±)-1- ([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], anovel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004;311(1):315-323.
7. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlledtrial of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72(5):439-446.
8. Lee DO, Ziman R, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2009;24(suppl 1):S443.
9. Bogan RK, Cramer Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010;85(6): 512-521.
10. Zomorodi K, Lal R, Atluri H, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Pharmacol 2009;49(9):1122.
11. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284(23):3043-3045.
12. Johns MW A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14(6):540-545.
13. Johns MW Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15(4):376-381.
14. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, crossover study. Neurology 2002;59(10):1573-1579.
15. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8(7-8):742-752.
16. Montplaisir J, Karrasch J, Haan J, et al. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21(10):1627-1635.
17. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75(1):92-97.
18. Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension ofthe PRELUDE study). Sleep Med 2008;9(5):537-541.